The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors for Patients with Anticancer Therapy: A Meta-Analysis of Cohort Studies
Background: Chemotherapy-induced cardiotoxicity is the leading cause of non-tumorrelated mortality among patients with tumors. Although sodium glucose cotransporter 2 inhibitors (SGLT2is) have been shown to confer cardiovascular benefits, their effects and safety profile in patients with cancer rema...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ubiquity Press
2025-06-01
|
| Series: | Global Heart |
| Subjects: | |
| Online Access: | https://account.globalheartjournal.com/index.php/up-j-gh/article/view/1440 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849717159689715712 |
|---|---|
| author | Gang Fan Hong Zuo Lin Lin Chao Xu Rui Yan |
| author_facet | Gang Fan Hong Zuo Lin Lin Chao Xu Rui Yan |
| author_sort | Gang Fan |
| collection | DOAJ |
| description | Background: Chemotherapy-induced cardiotoxicity is the leading cause of non-tumorrelated mortality among patients with tumors. Although sodium glucose cotransporter 2 inhibitors (SGLT2is) have been shown to confer cardiovascular benefits, their effects and safety profile in patients with cancer remain uncertain. The objective of this study was to assess the cardiovascular effects of SGLT2is in patients with cancer. Objective: We conducted a meta-analysis of cohort studies to compare the efficacy and safety of SGLT2is and placebo in patients with cancer. Results: A total of ten cohort studies, encompassing 85,185 patients, were included in this study. SGLT2is significantly decreased mortality (Risk ratios (RR) 0.52, 95% confidence interval (CI) (0.36, 0.75), I2 = 98%), heart failure (HF) (RR 0.43, 95% CI 0.24, 0.77, I2 = 75%), and arrhythmia (RR 0.33, 95% CI 0 .23, 0.49, I2 = 0%). In addition, SGLT2is decreased the incidence of adverse events. No significant difference was identified in hypoglycemia, ketoacidosis, and acute coronary syndrome (ACS). Conclusion: The present study suggest that sodium glucose cotransporter 2 inhibitors may be an efficacious and safe means for improving the prognosis of patients with cancer and diabetes. However, future large-scale randomized controlled trials are needed to further validate the results. |
| format | Article |
| id | doaj-art-6345ae3cfa1046c5bf4aa75354af25aa |
| institution | DOAJ |
| issn | 2211-8179 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Ubiquity Press |
| record_format | Article |
| series | Global Heart |
| spelling | doaj-art-6345ae3cfa1046c5bf4aa75354af25aa2025-08-20T03:12:45ZengUbiquity PressGlobal Heart2211-81792025-06-01201535310.5334/gh.14401421The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors for Patients with Anticancer Therapy: A Meta-Analysis of Cohort StudiesGang Fan0https://orcid.org/0000-0002-6616-3916Hong Zuo1Lin Lin2Chao Xu3Rui Yan4https://orcid.org/0009-0009-6324-4284Cardiology Department of Xianyang Central Hospital, Xianyang, Shaanxi Province, 712000Cardiology Department of Xianyang Central Hospital, Xianyang, Shaanxi Province, 712000Cardiovascular Hospital of the Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi Province, 710016Cardiology Department of Yangling Demonstration District Hospital, Xianyang, Shaanxi Province, 712100Cardiology Department of Beijing Luhe Hospital of Capital Medical University, 101149Background: Chemotherapy-induced cardiotoxicity is the leading cause of non-tumorrelated mortality among patients with tumors. Although sodium glucose cotransporter 2 inhibitors (SGLT2is) have been shown to confer cardiovascular benefits, their effects and safety profile in patients with cancer remain uncertain. The objective of this study was to assess the cardiovascular effects of SGLT2is in patients with cancer. Objective: We conducted a meta-analysis of cohort studies to compare the efficacy and safety of SGLT2is and placebo in patients with cancer. Results: A total of ten cohort studies, encompassing 85,185 patients, were included in this study. SGLT2is significantly decreased mortality (Risk ratios (RR) 0.52, 95% confidence interval (CI) (0.36, 0.75), I2 = 98%), heart failure (HF) (RR 0.43, 95% CI 0.24, 0.77, I2 = 75%), and arrhythmia (RR 0.33, 95% CI 0 .23, 0.49, I2 = 0%). In addition, SGLT2is decreased the incidence of adverse events. No significant difference was identified in hypoglycemia, ketoacidosis, and acute coronary syndrome (ACS). Conclusion: The present study suggest that sodium glucose cotransporter 2 inhibitors may be an efficacious and safe means for improving the prognosis of patients with cancer and diabetes. However, future large-scale randomized controlled trials are needed to further validate the results.https://account.globalheartjournal.com/index.php/up-j-gh/article/view/1440sglt2 inhibitorcancermeta-analysis |
| spellingShingle | Gang Fan Hong Zuo Lin Lin Chao Xu Rui Yan The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors for Patients with Anticancer Therapy: A Meta-Analysis of Cohort Studies Global Heart sglt2 inhibitor cancer meta-analysis |
| title | The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors for Patients with Anticancer Therapy: A Meta-Analysis of Cohort Studies |
| title_full | The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors for Patients with Anticancer Therapy: A Meta-Analysis of Cohort Studies |
| title_fullStr | The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors for Patients with Anticancer Therapy: A Meta-Analysis of Cohort Studies |
| title_full_unstemmed | The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors for Patients with Anticancer Therapy: A Meta-Analysis of Cohort Studies |
| title_short | The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors for Patients with Anticancer Therapy: A Meta-Analysis of Cohort Studies |
| title_sort | efficacy and safety of sodium glucose cotransporter 2 inhibitors for patients with anticancer therapy a meta analysis of cohort studies |
| topic | sglt2 inhibitor cancer meta-analysis |
| url | https://account.globalheartjournal.com/index.php/up-j-gh/article/view/1440 |
| work_keys_str_mv | AT gangfan theefficacyandsafetyofsodiumglucosecotransporter2inhibitorsforpatientswithanticancertherapyametaanalysisofcohortstudies AT hongzuo theefficacyandsafetyofsodiumglucosecotransporter2inhibitorsforpatientswithanticancertherapyametaanalysisofcohortstudies AT linlin theefficacyandsafetyofsodiumglucosecotransporter2inhibitorsforpatientswithanticancertherapyametaanalysisofcohortstudies AT chaoxu theefficacyandsafetyofsodiumglucosecotransporter2inhibitorsforpatientswithanticancertherapyametaanalysisofcohortstudies AT ruiyan theefficacyandsafetyofsodiumglucosecotransporter2inhibitorsforpatientswithanticancertherapyametaanalysisofcohortstudies AT gangfan efficacyandsafetyofsodiumglucosecotransporter2inhibitorsforpatientswithanticancertherapyametaanalysisofcohortstudies AT hongzuo efficacyandsafetyofsodiumglucosecotransporter2inhibitorsforpatientswithanticancertherapyametaanalysisofcohortstudies AT linlin efficacyandsafetyofsodiumglucosecotransporter2inhibitorsforpatientswithanticancertherapyametaanalysisofcohortstudies AT chaoxu efficacyandsafetyofsodiumglucosecotransporter2inhibitorsforpatientswithanticancertherapyametaanalysisofcohortstudies AT ruiyan efficacyandsafetyofsodiumglucosecotransporter2inhibitorsforpatientswithanticancertherapyametaanalysisofcohortstudies |